Share
Market Research Report

CHINA ULCERATIVE COLITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Segmentation
  • By Drug Therapy5-Aminosalicylates (Mesalazine, Balsalazide, Olsalazine, Others) · Monoclonal Antibodies (Vedolizumab, Adalimumab, Infliximab, Golimumab, Ustekinumab) · Steroids (Budesonide, Prednisone, Beclomethasone, Deflazacort, Others) · Antibiotics · Late-Stage Pipeline Molecules (Zeposia, Etrasimod, Others) · Other Drugs
  • By Dosage FormOral · Parenteral
  • By Distribution ChannelHospital Pharmacies · Retail Pharmacies · Online Pharmacies
  • Published In02 Mar 2026
  • Report CodeCMI4862
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026 - 2033
  1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview

    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Therapy
      • Market Snippet, By Dosage Form
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Recent Product Launch/Approval
    • Epidemiology
    • Mergers and Acquisitions
  4. China Ulcerative Colitis Market, By Drug Therapy, 2026-2033 (USD Mn)

    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2026 - 2033
      • Segment Trends
    • 5-Aminosalicylates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
        • Mesalazine
        • Balsalazide
        • Olsazaline
        • Others
    • Monoclonal Anibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
        • Vedolizumab
        • Adalimumab
        • Infliximab
        • Golimumab
        • Ustekimab
    • Steroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
        • Balsalazide
        • Prednisone
        • Beclomethasone
        • Deflazacort
        • Others
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
    • Late Stage Pipeline Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
        • Zeposia (ozanimod)
        • Etrasimod
        • Others
      • Other Drugs
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  5. China Ulcerative Colitis Market, By Dosage Form, 2026 - 2033 (USD Mn)

    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2026 - 2033
      • Segment Trends
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  6. China Ulcerative Colitis Market, By Distribution Channel, 2026 - 2033 (USD Mn)

    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2026 - 2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  7. Competitive Landscape

    • Company Profiles
      • AbbVie Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Celltrion Healthcare Co., Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Salix Pharmaceuticals
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Zeria Pharmaceutical Co., Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • InDex Pharmaceuticals
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Boehringer Ingelheim
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • EA Pharma Co., Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Theravance Biopharma
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • HUTCHMED
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  8. Section

    • References
    • Research Methodology
    • About us and Sales Contact